Paion Revenue and Competitors

PAION AG is a publicly listed specialty pharmaceutical company developing and aiming to commercialize innovative drugs to be used in out-patient and hospital-based sedation, anesthesia and critical care services. PAION's lead compound is remimazolam, an intravenous, ultra-short-acting and controllable benzodiazepine sedative/anesthetic drug candidate for which PAION has completed the clinical development for use in procedural sedation in the U.S. Outside the U.S., PAION has so far focused on the development of remimazolam for the indication of general anesthesia. A full clinical development program for general anesthesia was completed in Japan. In the EU, PAION initiated a Phase III trial in July 2018. Development of remimazolam in the indication intensive care unit (ICU) sedation is also part of the longer-term life-cycle plan for remimazolam. PAION is headquartered in Aachen (Germany) with an additional site in Cambridge (United Kingdom). PAION's vision is to become an acknowledged “PAIONeer” in sedation and anesthesia. PAION AG is listed on the Frankfurt Stock Exchange (Prime Standard Regulated Market, ticker symbol PA8, ISIN DE000A0B65S3).